Lauxera Capital Partners has made an investment in Caresyntax as part of a USD100 million Series C fundraise. Other new investors include PFM Health Sciences LP, Optum Ventures, Intel Capital, Vesalius Biocapital Partners, Arno Capital, and Reyazat Investments.
Caresyntax operates the leading, AI-driven, enterprise-grade platform for collecting, tracking, and analysing data on surgical procedures to enhance outcomes and patient safety. Through an innovative partnership strategy combined with direct focus on customer success, Caresyntax grew new contract value 250 per cent year-over-year in 2020. The company’s solutions are present in over 4,000 operating rooms (OR’s) today, adding four surgeries per minute to an increasingly compelling dataset already in the single-digit millions of procedures.
Caresyntax was founded in and maintains its primary R&D and operations hub in Berlin, but also has a significant presence in the United States. In Europe, the company has developed a particularly strong footprint in France and Germany. The University Hospital of Strasbourg is a leading customer, using the Caresyntax platform to enrich orthopaedic training, improve surgeon scores, and track patient risk. Caresyntax has also expanded rapidly into the US anchored by the acquisition of Syus – an OR operations and cost analytics solution – in late-2019 and collaborations with leading institutions like University of Iowa Health Care and University of Massachusetts Medical School.
Read more at Private Equity Wire
